scholarly journals sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation

2021 ◽  
Vol 11 (23) ◽  
pp. 11130
Author(s):  
Albert Topf ◽  
Vera Paar ◽  
Janine Grueninger ◽  
Bernhard Wernly ◽  
Kristen Kopp ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Early Intervention ◽  
Resistant Hypertension ◽  
Serum Levels ◽  
Clinical Parameter ◽  
Left Ventricular ◽  
Sympathetic Denervation ◽  
Renal Sympathetic Denervation ◽  
Term Therapy ◽  
Renal Sympathetic

Background: Renal sympathetic denervation (RSD) has provided promising data in its ability to treat therapy resistant arterial hypertension. The effect of RSD on sST-2, a promising biomarker for risk stratification in cardiovascular diseases, has so far not been systematically studied. Methods: We evaluated serum levels of sST-2 and clinical parameter including left ventricular mass (LVM) in 54 patients with resistant hypertension (RH) undergoing bilateral RSD at baseline as well as at one and/or three months. Results: After RSD, mean office blood pressure showed a significant decrease after one month (p < 0.001). On echocardiography a reduction of LVM was observed at three months (p < 0.01). This was accompanied by a significant decrease of sST-2 levels at three months (sST-2 baseline: 6310.1 ± 3246.0 pg/mL vs. sST-2 three months: 4703.8 ± 1585.9 pg/mL, p = 0.048). Furthermore, baseline sST-2 levels were positively correlated with systolic blood pressure at one month (r = 0.514, p < 0.01) but not three months, indicating a potential predictive value of sST-2 for early intervention success. Conclusion: In patients with RH, RSD is associated with a significant decrease of sST-2 levels after three months, indicating sST-2 to be involved in remodeling processes after RSD. Furthermore, lower sST-2 levels at baseline might be a potential predictor of early intervention success of RSD.

Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension

2015 ◽  
Vol 33 (12) ◽  
pp. 2512-2518 ◽  
Author(s):  
Sebastian Ewen ◽  
Oliver Dörr ◽  
Christian Ukena ◽  
Dominik Linz ◽  
Bodo Cremers ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Blood Pressure Variability ◽  
Sympathetic Denervation ◽  
Renal Sympathetic Denervation ◽  
Renal Sympathetic

scholarly journals Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea

Hypertension ◽  
2011 ◽  
Vol 58 (4) ◽  
pp. 559-565 ◽  
Author(s):  
Adam Witkowski ◽  
Aleksander Prejbisz ◽  
Elżbieta Florczak ◽  
Jacek Kądziela ◽  
Paweł Śliwiński ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Sleep Apnea ◽  
Glycemic Control ◽  
Resistant Hypertension ◽  
Sympathetic Denervation ◽  
Renal Sympathetic Denervation ◽  
Renal Sympathetic

scholarly journals Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension

Circulation ◽  
2013 ◽  
Vol 128 (2) ◽  
pp. 132-140 ◽  
Author(s):  
Felix Mahfoud ◽  
Christian Ukena ◽  
Roland E. Schmieder ◽  
Bodo Cremers ◽  
Lars C. Rump ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ambulatory Blood Pressure ◽  
Resistant Hypertension ◽  
Sympathetic Denervation ◽  
Renal Sympathetic Denervation ◽  
Pressure Changes ◽  
Renal Sympathetic

Abstract 15206: Sustained Beneficial Effects of Multi-Electrode Renal Sympathetic Denervation on Cardiac Adaptations in Resistant Hypertension: A 24-months Follow-Up Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Kyriakos Dimitriadis ◽  
Costas Tsioufis ◽  
Alexandros Kasiakogias ◽  
Panayiotis Vasileiou ◽  
Aggelos Papanikolaou ◽  
...  
Keyword(s):  
Diastolic Function ◽  
Resistant Hypertension ◽  
Interventricular Septum ◽  
Left Ventricular ◽  
Sympathetic Denervation ◽  
Renal Sympathetic Denervation ◽  
Number Of Patients ◽  
Lv Mass ◽  
Renal Sympathetic

Introduction: The favorable impact of renal sympathetic denervation (RDN) on cardiac parameters such as on left ventricular (LV) morphology, geometry and function has been shown up to 6 months after the procedure using diverse ablation systems. Hypothesis: Multi-electrode catheter-based renal sympathetic RDN may have favorable effects on LV structural and functional indices in patients with resistant hypertension after a follow-up of 24 months. Methods: Twenty patients with resistant hypertension [age: 57±10 years, 13 males, office blood pressure (BP): 182/97±19/18 mmHg under 4.5±0.6 drugs] who underwent RDN were followed-up for 24 months. A full transthoracic echocardiographic study was performed in all patients and LV mass was calculated using the Devereux formula and was indexed for body surface area and height. Results: Average office BP was reduced to 148±21/85±14 mmHg at 12 months and to 143±23/80±14 mmHg at 24 months (p<0.001 for all). In the RDN group, LV mass index was significantly reduced from 136±20.1 g/m 2 (56.5±8.7 g/m 2.7 ) to 121±16.6 g/m 2 (50.6±6 g/m 2.7 ) at 12 months and to 115.6±23.3 g/m 2 (48.8±9.3 g/m 2.7 ) at 24 months (p<0.01 for all). RDN decreased mean interventricular septum thickness from 12.1±1.2 mm to 11.4±0.9 mm at 12 months and to 11.3±0.9 mm at 24 months (p<0.05 for all). After RDN, the number of patients with concentric LV hypertrophy (i.e. relative wall thickness >0.42 and LV mass >48 g/m 2.7 for male and >44 g/m 2.7 for female) decreased from 16 patients (80%) at baseline to 10 patients (50%) at 12 months, and to 7 patients (36.8%) at 24 months. Regarding diastolic function RDN caused an increase in mitral valve E'/A' ratio from 0.62±0.28 to 0.70±0.25 at 12 months and to 0.84±0.32 at 24 months (p<0.05 for all) and a decrease in the E/E' ratio from 14.8±6.1 to 11.8±3.7 at 12 months and to 9.7±4 at 24 months (p<0.05 for all). Conclusions: This the first study to show that multi-electrode RDN results in a significant and sustained improvement of diastolic function and attenuation of LV mass index in increased cardiovascular risk resistant hypertensive patients after a follow-up of 24 months. These results suggest long-term pleiotropic cardiovascular benefits of RDN therapy in the setting of resistant hypertension.

Sign in / Sign up

Export Citation Format

Share Document